A. Courtin

发表

Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation.

J. Foidart, C. Munaut, S. Blacher, 2014, The Journal of endocrinology.

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

D. Tuveson, J. Griffiths, D. Jodrell, 2014, British Journal of Cancer.

Quantitation of ERK1/2 inhibitor cellular target occupancies with a reversible slow off-rate probe

P. Nordlund, O. Surova, M. O’Reilly, 2019 .

Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations

P. Pujol, S. Delaloge, P. Forgez, 2016, Oncotarget.

Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.

R. Bouvier, P. Clézardin, J. Guglielmi, 2005, Cancer research.

Ulipristal acetate does not impact human normal breast tissue.

P. Forgez, A. Gompel, Myriam Vilasco, 2012, Human reproduction.

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

D. Jodrell, F. Richards, R. Boyce, 2015, Cancer research.

Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer

D. Tuveson, D. Jodrell, B. Krippendorff, 2013, PloS one.

SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.

A. Harel-Bellan, S. Ait-Si-Ali, P. Clézardin, 2003, Cancer research.

Advances in Brief SiRNA-mediated Inhibition of Vascular Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth 1

A. Harel-Bellan, S. Ait-Si-Ali, P. Clézardin, 2003 .

Glucocorticoid receptor and breast cancer

P. Forgez, A. Gompel, Myriam Vilasco, 2011, Breast Cancer Research and Treatment.

Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells

D. Cimino, D. Taverna, A. Faussat, 2011, Breast Cancer Research and Treatment.

Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells

Sylvie Chevillard, P. Romeo, S. Altmeyer-Morel, 2009, Carcinogenesis.

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

H. Saini, J. Lyons, N. Thompson, 2016, British Journal of Cancer.

Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2

S. Cook, K. Balmanno, H. Saini, 2019, Molecular Cancer Therapeutics.

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK

C. Murray, V. Berdini, J. Lyons, 2021, Molecular Cancer Therapeutics.

Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, L. Fazal, 2021, Journal of medicinal chemistry.

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, J. Castro, 2018, Journal of medicinal chemistry.

Progestins induce catalase activities in breast cancer cells through PRB isoform: Correlation with cell growth inhibition

P. Forgez, W. Rostène, A. Gompel, 2009, The Journal of Steroid Biochemistry and Molecular Biology.

TITLE: CHK1 inhibition synergizes with gemcitabine initially by destabilizing the DNA replication apparatus AUTHORS AND AFFILIATIONS:

D. Jodrell, R. Boyce, Francés, 2015 .

Quantitation of ERK1/2 inhibitor cellular target occupancies with a reversible slow off-rate probe† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc02754d

P. Nordlund, O. Surova, M. O’Reilly, 2018, Chemical science.

A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysis

V. Ostapenko, N. Badri, E. Mickiewicz, 2001 .

Prostate Inhibitor Thrombospondin-1 in Normal and Neoplastic Androgens Repress the Expression of the Angiogenesis

R. Bouvier, P. Clézardin, J. Guglielmi, 2004 .